Work

Deferasirox (Exjade®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.

Year: 2008

Type: article

Source: Blood

DOI: 10.1182/blood.v112.11.1420.1420

Authors: Elliott Vichinsky, Thomas Coates, Alexis A Thompson, Françoise Bernaudin, Martha Rodriguez, Lisa Rojkjaer, Matthew M Heeney

Institutions: Children's Hospital Los Angeles, Lurie Children's Hospital, Hôpital Intercommunal de Créteil, Novartis (United States), Novartis (Switzerland), Boston Children's Hospital

Language: English

Topic: Hemoglobinopathies and Related Disorders

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2554055446

FWCI: 1.071

Cites:

Cited by: 10

Related to: 10